Using a pharmacogenetic clinical decision support system to improve psychopharmacotherapy dosing in patients with affective disorders

Застрожин, М. С.; Skryabin, Valentin Yurievich; Sorokin, Alexander; Бузик, О. Ж.; Bedina, Inessa A.; Grishina, Elena A.; Ryzhikova, Kristina; Shipitsyn, V. V.; Bryun, Evgeny А.; Сычев, Д. А.

doi:10.1515/dmpt-2019-0033

Cited by 3 publications

(16 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One study included a male-only population. 15 Male and female participants each represented approximately half of study populations in 4 articles; 13,14,17,19 female participants were a greater proportion in 2 studies (ranging from 72% to 75.93%) 12,18 and male participants were the greater proportion in the other 2 studies. 11,16…”

Section: Patient Populationmentioning

confidence: 98%

“…Of the potentially relevant articles, 55 publications were excluded for various reasons and 11 publications met the inclusion criteria and were included in this report. These comprised 1 SR, 9 1 HTA, 10 4 RCTs, [11][12][13][14][15] 1 NRS, 16 1 cohort study with historical control, 17 and 2 uncontrolled before-and-after studies. 18,19 Of the RCTs, 2 publications by Ruaño et al reported results from the same trial: 13,14 1 study described the main results 13 and the other summarized findings based on subgroup analyses.…”

Section: Quantity Of Research Availablementioning

confidence: 99%

“…The authors of the included SR were from Qatar 9 and those who authored the HTA 10 were from Canada. Of the remaining 8 studies (where 1 was reported in 2 publications), 4 were conducted in the US, 11,13,14,18,19 1 in Canada, 12 1 in Russia, 15 1 in China, 16 and 1 in Germany 17 (the primary author's affiliations were both Switzerland and Germany).…”

Section: Country Of Originmentioning

confidence: 99%

“…Populations in the included primary studies were adults who had a variety of conditions such as MDD, bipolar disorder, posttraumatic stress disorder (PTSD), and generalized anxiety disorder. [11][12][13][14][15][16][17][18][19] One study 15 included patients who had comorbid affective disorder and alcohol addiction. The studies included in the current report varied in their descriptions of whether patients had already tried previous AD therapy that had been unsuccessful.…”

Section: Patient Populationmentioning

confidence: 99%

“…The studies included in the current report varied in their descriptions of whether patients had already tried previous AD therapy that had been unsuccessful. Five studies reported in 6 publications took place in single hospital/health care centre setting, [13][14][15][16][17][18] 1 study was in a veteran centre, 11 1 study was in an urban community pharmacy, 12 and 1 study took place in an outpatient centre. 19 Total study population sizes ranged from 15 to 1,459 participants.…”

Section: Patient Populationmentioning

confidence: 99%

See 4 more Smart Citations

Pharmacogenomic Testing in Depression: A 2021 Update

Darvesh¹,

Horton²,

Lê³

2022

cjht

View full text Add to dashboard Cite

An update to a 2020 CADTH Rapid Review was conducted to capture new literature published since 2019 examining the effectiveness of drug treatment informed by genetic testing compared to usual care for adults with depression. Eleven studies were identified: 1 systematic review, 1 health technology assessment, 4 randomized controlled trials reported in 5 publications, 1 non-randomized study, 1 cohort study with historical control, and 2 uncontrolled before-and-after studies. Similar to the conclusions of the 2020 CADTH report, the effectiveness of gene testing for treating depression was unclear. In patients with depression, some studies showed that there were improvements in the clinical effectiveness outcomes in those who received gene testing and other studies showed that there was no difference in outcomes between those who received gene testing and those who did not. No studies showed that gene testing resulted in worse outcomes compared to those who did not receive gene testing. In the current report, the were several limitations across studies such as poor design, inclusion of subjectively measured outcomes, small sample sizes, and a focus on hospital settings ― all of which may not be generalizable to other populations.

show abstract

Section: Patient Populationmentioning

confidence: 98%

Section: Quantity Of Research Availablementioning

confidence: 99%

Section: Country Of Originmentioning

confidence: 99%

Section: Patient Populationmentioning

confidence: 99%

Section: Patient Populationmentioning

confidence: 99%

See 3 more Smart Citations

Pharmacogenomic Testing in Depression: A 2021 Update

Darvesh¹,

Horton²,

Lê³

2022

cjht

View full text Add to dashboard Cite

show abstract

Genetically Guided Precision Medicine Clinical Decision Support Tools: A Systematic Review

Johnson,

Del Fiol,

Kawamoto

et al. 2023

Preprint

View full text Add to dashboard Cite

Objective Patient care using genetics presents complex challenges. Clinical decision support (CDS) tools are a potential solution because they provide patient-specific risk assessments and/or recommendations at the point of care. This systematic review evaluated literature on CDS systems which have been implemented to support genetically guided precision medicine (GPM). Materials and Methods A comprehensive search was conducted in MEDLINE and Embase, encompassing Jan 1st, 2011 to March 14th, 2023. The review included primary English peer-reviewed research articles studying humans, focused on use of computers to guide clinical decision making and delivering genetically guided, patient-specific assessments and/or recommendations to healthcare providers and/or patients. Results The search yielded 3,832 unique articles. After screening, 41 articles were identified that met the inclusion criteria. Alerts and reminders were the most common form of CDS used. 27 systems were integrated with the electronic health record; 2 of those used standards-based approaches for genomic data transfer. Three studies used a framework to analyze the implementation strategy. Discussion Findings include limited use of standards-based approaches for genomic data transfer, system evaluations that do not employ formal frameworks, and inconsistencies in the methodologies used to assess genetic CDS systems and their impact on patient outcomes. Conclusion We recommend that future research on CDS system implementation for genetically guided precision medicine should focus on implementing more CDS systems, utilization of standards-based approaches, user-centered design, exploration of alternative forms of CDS interventions, and use of formal frameworks to systematically evaluate genetic CDS systems and their effects on patient care.

show abstract

Problems of integrating medical science, image and practical health care: focus on personalized medicine

Сычёв

2020

Fgen_Fgenom

View full text Add to dashboard Cite

On the example of technologies of personalization of pharmacotherapy based on biomarkers of the processes of absorption, distribution, metabolism and excretion of drugs (ADME-processes), the methodology of the results of scientific research into the educational process within the system of continuous medical education of doctors into the real clinical practice is presented. This methodology has been developed and implemented in the Russian Medical Academy of Continuing Professional Education.

show abstract

Using a pharmacogenetic clinical decision support system to improve psychopharmacotherapy dosing in patients with affective disorders

Cited by 3 publications

References 44 publications

Pharmacogenomic Testing in Depression: A 2021 Update

Pharmacogenomic Testing in Depression: A 2021 Update

Genetically Guided Precision Medicine Clinical Decision Support Tools: A Systematic Review

Problems of integrating medical science, image and practical health care: focus on personalized medicine

Contact Info

Product

Resources

About